【作者】 郝新保；

【导师】 范清宇；

【作者基本信息】 第四军医大学 ， 外科学， 2000， 博士

【摘要】 随着肿瘤研究的不断深入，传统的手术方法有了很大改进，使得骨肉瘤的局部控制成为可能。然而，尽管联合了化疗和放疗，仍有大约40％的患者发生肺转移，成为治疗失败的主要原因。 以CTL识别为基础的技术路线的建立，使人们在多种肿瘤中发现了新的抗原，尤其是黑色素瘤MAGE、MART等抗原的发现，极大地促进了主动性免疫治疗的发展，数个治疗方案已经进入临床试验阶段，以主动性免疫治疗为主的生物治疗正日益成为一种新的有效治疗手段，但遗憾的是目前尚未在骨肉瘤中找到类似的CTL识别抗原用于主动性免疫治疗。 为了提高骨肉瘤细胞的免疫原性，本研究采用专业的抗原提呈细胞巨噬细胞与骨肉瘤细胞融合的技术路线，探讨融合瘤苗在更多还原

【Abstract】 Along with the development of cancer research, the traditional operation scheme have been changed in many ways, that makes the local control of osteosarcoma become possible. But the almost 40% lung metastasis tends to result in treatment failure in spite of combined with radiotherapy and chemotherapy.The findings of tumor specific antigen recognized by CTL, especially the melanoma antigens MAGE and MART, have promoted the active immunotherapy in large extent and then several clinical trails are in progress. The immunotherapy based on a greater appreciation of the mechanisms by which tumor-specific cytolytic cells are generated is becoming a new approach in cancer treatment.Central to the induction of CTL responses are professional antigen-presenting cells, including macrophages and dendritic cells, which present tumor antigen to the immune system in the context of major更多还原